AVACTA 产品代理
AVACTA 产品代理
Avacta生命科学有两个部门;治疗和诊断。
Avacta的治疗部门，位于英国剑桥，结合其两个专有平台——Affimer®生物疗法和pre - |CISIONTM肿瘤靶向化疗，开发新型癌症免疫疗法。通过这种方法，该公司旨在解决大多数患者对当前免疫疗法缺乏持久反应的问题。
Affimer®平台是一种基于天然人类蛋白质的新型生物疗法。它是Avacta的专有治疗平台，其知识产权涵盖多个专利家族。
Avacta公司拥有专利的pre - |CISIONTM靶向化疗平台，仅在肿瘤中释放活性药物，从而限制了全身暴露，提高了这些强大的抗癌治疗的整体安全性和治疗潜力。Avacta于2021年夏季将其首个CISIONTM前候选药物AVA6000投入临床，AVA6000是阿霉素标准治疗的一种靶点。
oncology drug
Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative, propitiatory Affimer® and pre|CISION™ platforms
Avacta Life Sciences has two divisions; therapeutics and diagnostics.
Avacta’s therapeutics division, based in Cambridge, U.K. develops novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.
The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta took its first pre|CISIONTM drug candidate AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic in summer 2021.
